OTC Markets EXMKT - Delayed Quote USD

Adocia SA (ADOCY)

11.80

0.00

(0.00%)

At close: May 7 at 4:00:00 PM EDT

ADOCIA Announces its Annual Shareholders’ Meeting to be Held on June 11th, 2025 in Paris

LYON, France, May 21, 2025--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, announced today that it will hold its annual shareholders’ meeting ("AGM") on June 11th, 2025, at 2:00 pm, in the Jones Day’s offices, Hotel de Talleyrand, 2 rue Saint Florentin, 75001 Paris.

Business Wire 20 hours ago

ADOBS.PA

ADOC.PA
ADOCIA Reports First Quarter 2025 Financial Results and Provides a Business Update

LYON, France, May 14, 2025--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the first quarter of 2025 and provides a business update.

Business Wire 7 days ago

ADOBS.PA

ADOC.PA
ADOCIA to Present New Data on AdoShell® at Upcoming Scientific Conferences – Showcasing Potential Curative Treatment for Type 1 Diabetes

LYON, France, April 28, 2025--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity (the "Company"), today announced the latest preclinical data from its innovative AdoShell® technology platform have been selected for presentations at four upcoming scientific conferences.

Business Wire 23 days ago

ADOBS.PA

ADOC.PA
ADOCIA Announces Full Year 2024 Financial Results and Provides a Corporate and Financial Update

LYON, France, April 17, 2025--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity (the "Company"), announces today its annual financial results as of December 31, 2024. The consolidated statements contained herein were approved by Adocia’s board of directors on April 16, 2025. Audit procedures have been completed, and the audi

Business Wire last month

ADOBS.PA

ADOC.PA
Number of Shares and Voting Rights of ADOCIA as of March 31st, 2025

LYON, France, April 11, 2025--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French "Code de Commerce" and article 223-16 of the General Regulation of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF"), ADOCIA SA, a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutio

Business Wire last month

ADOBS.PA

ADOC.PA
ADOCIA Announces the Successful Completion of a €9.7 Million Private Placement, Extending its Cash Runway to Q2 2026

LYON, France, February 26, 2025--Regulatory News: NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA

Business Wire 2 months ago

ADOC.PA
ADOCIA Reports Fourth Quarter 2024 Financial Results and Provides a Business Update

LYON, France, February 25, 2025--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity (the "Company"), reports financial results for the fourth quarter of 2024 and provides a business update.

Business Wire 2 months ago

ADOC.PA
Number of Shares and Voting Rights of ADOCIA as of January 31st, 2025

LYON, France, February 14, 2025--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF"), ADOCIA SA (Paris:ADOC), a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for t

Business Wire 3 months ago

ADOC.PA
ADOCIA Announces Half-Year Report on Adocia’s Liquidity Agreement with Kepler Capital Markets

LYON, France, January 22, 2025--Regulatory News: Under the liquidity agreement entrusted by Adocia (Euronext Paris: FR0011184241 – ADOC) to Kepler Capital Markets, the following resources were listed on the liquidity account on December 31, 2024:

Business Wire 3 months ago

ADOC.PA
Number of Shares and Voting Rights of ADOCIA as of December 31st, 2024

LYON, France, January 17, 2025--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF"), ADOCIA SA, a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment o

Business Wire 4 months ago

ADOC.PA
ADOCIA Announces Its Participation at Upcoming Investor Conferences in 2025

LYON, France, December 23, 2024--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, today announced that its management team are scheduled to participate in the following upcoming investor conferences:

Business Wire 4 months ago

ADOC.PA
ADOCIA Announces its Financial Calendar for 2025

LYON, France, December 19, 2024--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, today announced its financial calendar for 2025.

Business Wire 4 months ago

ADOC.PA
ADOCIA and Tonghua Dongbao Announce the Final Dosing in a Phase 3 Clinical Study of BioChaperone® Lispro, Milestone Associated with a $10 Million Payment

LYON, France, December 12, 2024--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, today announced the completion of the final dosing of the last Type 2 diabetes patient in a Phase 3 clinical trial evaluating BioChaperone® Lispro, the Company’s novel ultra-rapid insulin.

Business Wire 5 months ago

ADOC.PA
Number of Shares and Voting Rights of ADOCIA as of November 30th, 2024

LYON, France, December 04, 2024--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") ADOCIA SA (Paris:ADOC), a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for th

Business Wire 5 months ago

ADOC.PA
Number of Shares and Voting Rights of ADOCIA as of October 31st, 2024

LYON, France, November 08, 2024--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") charter ADOCIA SA (Paris:ADOC), a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solution

Business Wire 6 months ago

ADOC.PA
ADOCIA Reports Third Quarter 2024 Financial Results and Provides a Business Update

LYON, France, October 30, 2024--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the third quarter of 2024 and provides a business update.

Business Wire 6 months ago

ADOC.PA
ADOCIA Announces Patenting Stable Combinations of GLP-1 and Amylin Analogs for the Treatment of Obesity and Diabetes Using Its BioChaperone® Platform

LYON, France, October 15, 2024--Regulatory News: Adocia (Euronext Paris: FR0011184241 - ADOC), a clinical-stage biopharmaceutical company specialized in the discovery and development of innovative therapeutic solutions for the treatment of diabetes and obesity, announced today that it has filed patents of stable formulations of hormone combinations for the treatment of obesity and diabetes using its BioChaperone® platform.

Business Wire 7 months ago

ADOC.PA
Number of Shares and Voting Rights of ADOCIA as of September 30th, 2024

LYON, France, October 08, 2024--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") charter ADOCIA SA (Paris:ADOC), a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions

Business Wire 7 months ago

ADOC.PA
ADOCIA Announces Appointment of Mathieu‑William Gilbert as Chief Financial Officer

LYON, France, September 23, 2024--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, today announced the appointment of Mathieu-William Gilbert as Chief Financial Officer. He succeeds Valérie Danaguezian, who has held this position since 2005.

Business Wire 7 months ago

ADOC.PA
Number of Shares and Voting Rights of ADOCIA as of August 31st, 2024

LYON, France, September 20, 2024--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") charter ADOCIA SA (Paris:ADOC), a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutio

Business Wire 7 months ago

ADOC.PA

Performance Overview

Return	ADOCY	CAC 40 (^FCHI)
YTD	--	+5.90%
1-Year	--	-3.41%
3-Year	--	+24.36%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Adocia SA (ADOCY)

ADOCIA Announces its Annual Shareholders’ Meeting to be Held on June 11th, 2025 in Paris

ADOCIA Reports First Quarter 2025 Financial Results and Provides a Business Update

ADOCIA to Present New Data on AdoShell® at Upcoming Scientific Conferences – Showcasing Potential Curative Treatment for Type 1 Diabetes

ADOCIA Announces Full Year 2024 Financial Results and Provides a Corporate and Financial Update

Number of Shares and Voting Rights of ADOCIA as of March 31st, 2025

ADOCIA Announces the Successful Completion of a €9.7 Million Private Placement, Extending its Cash Runway to Q2 2026

ADOCIA Reports Fourth Quarter 2024 Financial Results and Provides a Business Update

Number of Shares and Voting Rights of ADOCIA as of January 31st, 2025

ADOCIA Announces Half-Year Report on Adocia’s Liquidity Agreement with Kepler Capital Markets

Number of Shares and Voting Rights of ADOCIA as of December 31st, 2024

ADOCIA Announces Its Participation at Upcoming Investor Conferences in 2025

ADOCIA Announces its Financial Calendar for 2025

ADOCIA and Tonghua Dongbao Announce the Final Dosing in a Phase 3 Clinical Study of BioChaperone® Lispro, Milestone Associated with a $10 Million Payment

Number of Shares and Voting Rights of ADOCIA as of November 30th, 2024

Number of Shares and Voting Rights of ADOCIA as of October 31st, 2024

ADOCIA Reports Third Quarter 2024 Financial Results and Provides a Business Update

ADOCIA Announces Patenting Stable Combinations of GLP-1 and Amylin Analogs for the Treatment of Obesity and Diabetes Using Its BioChaperone® Platform

Number of Shares and Voting Rights of ADOCIA as of September 30th, 2024

ADOCIA Announces Appointment of Mathieu‑William Gilbert as Chief Financial Officer

Number of Shares and Voting Rights of ADOCIA as of August 31st, 2024

Performance Overview